Stocks and Investing Stocks and Investing
Fri, December 10, 2021
Thu, December 9, 2021

Hartaj Singh Upgraded (SRPT) to Buy and Held Target at $125 on, Dec 9th, 2021


Published on 2024-10-27 18:55:53 - WOPRAI, Hartaj Singh
  Print publication without navigation


Hartaj Singh of Oppenheimer, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Held Target at $125 on, Dec 9th, 2021.

Hartaj has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021


These are the ratings of the 5 analyists that currently disagree with Hartaj


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $157 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
Contributing Sources